A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease

Neuroscience Research

Volumn 52, Issue 2, 2005, Pages 185-194

  Tomiyama, Masahiko ^a   Kimura, Tamaki ^a   Maeda, Tetsuya ^a   Kannari, Kazuya ^a   Matsunaga, Muneo ^a   Baba, Masayuki ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

6 Hydroxydopamine; Dynorphin; Dyskinesia; Enkephalin; Glutamic acid decarboxylase; Priming

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 6 HYDROXYTRYPTAMINE; DYNORPHIN; GLUTAMATE DECARBOXYLASE; LEVODOPA; MESSENGER RNA; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; ANTIPARKINSON AGENT; SEROTONIN AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; DRUG EFFECT; DYSKINESIA; GENETIC CODE; MALE; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ROTATION; ANIMAL; ANIMAL BEHAVIOR; DISEASE MODEL; DRUG COMBINATION; FEMALE; IN SITU HYBRIDIZATION; METABOLISM; WISTAR RAT;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; DYNORPHINS; DYSKINESIA, DRUG-INDUCED; FEMALE; GLUTAMATE DECARBOXYLASE; IN SITU HYBRIDIZATION; LEVODOPA; PARKINSON DISEASE; RATS; RATS, WISTAR; SEROTONIN AGONISTS;

EID: 18944406853     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neures.2005.03.004     Document Type: Article

References (49)

1. P.R. Albert, Q.Y. Zhou, H.H. Van Tol, J.R. Bunzow, and O. Civelli Cloning, functional expression, and mRNA tissue distribution of the rat 5-hydroxytryptamine1A receptor gene J. Biol. Chem. 265 1990 5825 5832
2. G.D. Bartoszyk, C. Van Ammmmsterdam, H.E. Greiner, W. Rautenberg, H. Russ, and C.A. Seyfried Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile J. Neural. Transm. 111 2004 113 126
3. F. Bibbiani, J.D. Oh, and T.N. Chase Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models Neurology 57 2001 1829 1834
4. V. Bonifati, E. Fabrizio, R. Cipriani, N. Vanacore, and G. Meco Buspirone in levodopa-induced dyskinesias Clin. Neuropharmacol. 17 1994 73 82
5. R. Bordet, S. Ridray, S. Carboni, J. Diaz, P. Sokoloff, and J.C. Schwartz Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa Proc. Natl. Acad. Sci. U.S.A. 94 1997 3363 3367
6. R.J. Carey Chronic l-dopa treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance Brain Res. 568 1991 205 214
7. J.M. Casanovas, M.T. Vilaro, G. Mengod, and F. Artigas Differential regulation of somatodendritic serotonin 5-HT1A receptors by 2-week treatments with the selective agonists alnespirone (S-20499) and 8-hydroxy-2-(di-n- propylamino)tetralin: microdialysis and autoradiographic studies in rat brain J. Neurochem. 72 1999 262 272
8. M.A. Cenci, K. Campbell, and A. Bjorklund Neuropeptide messenger RNA expression in the 6-hydroxydopamine-lesioned rat striatum reinnervated by fetal dopaminergic transplants: differential effects of the grafts on preproenkephalin, preprotachykinin and prodynorphin messenger RNA levels Neuroscience 57 1993 275 296
9. M.A. Cenci, C.S. Lee, and A. Bjorklund l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA Eur. J. Neurosci. 10 1998 2694 2706
10. T.N. Chase, and J.D. Oh Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications Ann. Neurol. 47 2000 S122 S129
11. O. Civelli, J. Douglass, A. Goldstein, and E. Herbert Sequence and expression of the rat prodynorphin gene Proc. Natl. Acad. Sci. U.S.A. 82 1985 4291 4295
12. R. Cortes, S. Ceccatelli, M. Schalling, and T. Hokfelt Differential effects of intracerebroventricular colchicine administration on the expression of mRNAs for neuropeptides and neurotransmitter enzymes, with special emphasis on galanin: an in situ hybridization study Synapse 6 1990 369 391
13. T.M. Engber, Z. Susel, S. Kuo, C.R. Gerfen, and T.N. Chase Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats Brain Res. 552 1991 113 118
14. C.R. Gerfen, T.M. Engber, L.C. Mahan, Z. Susel, T.N. Chase, F.J. Monsma Jr., and D.R. Sibley D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons Science 250 1990 1429 1432
15. B. Henry, A.R. Crossman, and J.M. Brotchie Characterization of enhanced behavioral responses to l-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease Exp. Neurol. 151 1998 334 342
16. R.D. Howells, D.L. Kilpatrick, R. Bhatt, J.J. Monahan, M. Poonian, and S. Udenfriend Molecular cloning and sequence determination of rat preproenkephalin cDNA: sensitive probe for studying transcriptional changes in rat tissues Proc. Natl. Acad. Sci. U.S.A. 81 1984 7651 7655
17. B.L. Jacobs, and E.C. Azmitia Structure and function of the brain serotonin system Physiol. Rev. 72 1992 165 229
18. J.L. Juncos, T.M. Engber, R. Raisman, Z. Susel, F. Thibaut, A. Ploska, Y. Agid, and T.N. Chase Continuous and intermittent levodopa differentially affect basal ganglia function Ann. Neurol. 25 1989 473 478
19. K. Kannari, K. Kurahashi, M. Tomiyama, T. Maeda, A. Arai, M. Baba, T. Suda, and M. Matsunaga Tandospirone citrate, a selective 5-HT1A agonist, alleviates l-DOPA-induced dyskinesia in patients with Parkinson's disease No To Shinkei. 54 2002 133 137
20. K. Kannari, H. Tanaka, T. Maeda, M. Tomiyama, T. Suda, and M. Matsunaga Reserpine pretreatment prevents increases in extracellular striatal dopamine following l-DOPA administration in rats with nigrostriatal denervation J. Neurochem. 74 2000 263 269
21. K. Kannari, H. Yamato, H. Shen, M. Tomiyama, T. Suda, and M. Matsunaga Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered l-DOPA in the striatum with nigrostriatal denervation J. Neurochem. 76 2001 1346 1353
22. B. Kleedorfer, A.J. Lees, and G.M. Stern Buspirone in the treatment of levodopa induced dyskinesias J. Neurol. Neurosurg. Psychiatry 54 1991 376 377
23. Y. Kobayashi, D.L. Kaufman, and A.J. Tobin Glutamic acid decarboxylase cDNA: nucleotide sequence encoding an enzymatically active fusion protein J. Neurosci. 7 1987 2768 2772
24. M.C. Kurth, J.W. Tetrud, C.M. Tanner, I. Irwin, G.T. Stebbins, C.G. Goetz, and J.W. Langston Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations Neurology 43 1993 1698 1703
25. A. Lopez, A. Muñoz, M.J. Guerra, and J.L. Labandeira-Garcia Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum Neuroscience 103 2001 639 651
26. T. Maeda, K. Kannari, H. Shen, A. Arai, M. Tomiyama, M. Matsunaga, and T. Suda Rapid induction of serotonergic hyperinnervation in the adult rat striatum with extensive dopaminergic denervation Neurosci. Lett. 343 2003 17 20
27. T. Maeda, K. Kannari, T. Suda, and M. Matsunaga Loss of regulation by presynaptic dopamine D2 receptors of exogenous l-DOPA-derived dopamine release in the dopaminergic denervated striatum Brain Res. 817 1999 185 191
28. E. Melamed, F. Hefti, J. Liebman, A.J. Schlosberg, and R.J. Wurtman Serotonergic neurones are not involved in action of l-dopa in Parkinson's disease Nature 283 1980 772 774
29. J.A. Obeso, M.C. Rodriguez-Oroz, M. Rodriguez, R. Macias, L. Alvarez, J. Guridi, J. Vitek, and M.R. DeLong Pathophysiologic basis of surgery for Parkinson's disease Neurology 55 2000 S7 S12
30. C.W. Olanow, and M.F. Brin Surgical therapies for Parkinson's disease. A physician's perspective Adv. Neurol. 86 2001 421 433
31. C.W. Olanow, P. Damier, C.G. Goetz, T. Mueller, J. Nutt, O. Rascol, A. Serbanescu, F. Deckers, and H. Russ Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study) Clin. Neuropharmacol. 27 2004 58 62
32. C.W. Olanow, and J.A. Obeso Preventing levodopa-induced dyskinesias Ann. Neurol. 47 2000 S167 S176
33. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates 1986 Academic Press New York
34. M. Pompeiano, J.M. Palacios, and G. Mengod Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding J. Neurosci. 12 1992 440 453
35. F. Radja, L. Descarries, K.M. Dewar, and T.A. Reader Serotonin 5-HT1 and 5-HT2 receptors in adult rat brain after neonatal destruction of nigrostriatal dopamine neurons: a quantitative autoradiographic study Brain Res. 606 1993 273 285
36. O. Rascol Medical treatment of levodopa-induced dyskinesias Ann. Neurol. 47 2000 S179 S188
37. J.I. Sage, S. Trooskin, P.K. Sonsalla, R. Heikkila, and R.C. Duvoisin Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism Ann. Neurol. 24 1988 87 89
38. A. Schrag, and N. Quinn Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study Brain 123 2000 2297 2305
39. J. Segovia, N.J. Tillakaratne, K. Whelan, A.J. Tobin, and K. Gale Parallel increases in striatal glutamic acid decarboxylase activity and mRNA levels in rats with lesions of the nigrostriatal pathway Brain Res. 529 1990 345 348
40. J.J. Soghomonian, and M.F. Chesselet Effects of nigrostriatal lesions on the levels of messenger RNAs encoding two isoforms of glutamate decarboxylase in the globus pallidus and entopeduncular nucleus of the rat Synapse 11 1992 124 133
41. J.J. Soghomonian, G. Doucet, and L. Descarries Serotonin innervation in adult rat neostriatum. I. Quantified regional distribution Brain Res. 425 1987 85 100
42. H. Tanaka, K. Kannari, T. Maeda, M. Tomiyama, T. Suda, and M. Matsunaga Role of serotonergic neurons in l-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats Neuroreport 10 1999 631 634
43. M.D. Taylor, M.L. De Ceballos, S. Rose, P. Jenner, and C.D. Marsden Effects of a unilateral 6-hydroxydopamine lesion and prolonged l-3, 4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia Eur. J. Pharmacol. 219 1992 183 192
44. M. Tomiyama, T. Kimura, T. Maeda, H. Tanaka, K. Furusawa, K. Kurahashi, and M. Matsunaga Expression of metabotropic glutamate receptor mRNAs in the human spinal cord: implications for selective vulnerability of spinal motor neurons in amyotrophic lateral sclerosis J. Neurol. Sci. 189 2001 65 69
45. M. Tomiyama, T. Kimura, T. Maeda, H. Tanaka, K. Kannari, and M. Baba Upregulation of striatal adenosine A2A receptor mRNA in 6-hydroxydopamine- lesioned rats intermittently treated with l-DOPA Synapse 52 2004 218 222
46. M. Tomiyama, F. Mori, T. Kimura, N. Ichinohe, K. Wakabayashi, M. Matsunaga, and M. Baba Hypertrophy of medial globus pallidus and substantia nigra reticulata in 6-hydroxydopamine-lesioned rats treated with l-DOPA: implication for l-DOPA-induced dyskinesia in Parkinson's disease Neuropathology 24 2004 290 295
47. M. Tomiyama, R. Rodriguez-Puertas, R. Cortes, A. Christnacher, B. Sommer, A. Pazos, J.M. Palacios, and G. Mengod Differential regional distribution of AMPA receptor subunit messenger RNAs in the human spinal cord as visualized by in situ hybridization Neuroscience 75 1996 901 915
48. P. Vernier, J.F. Julien, P. Rataboul, O. Fourrier, C. Feuerstein, and J. Mallet Similar time course changes in striatal levels of glutamic acid decarboxylase and proenkephalin mRNA following dopaminergic deafferentation in the rat J. Neurochem. 51 1988 1375 1380
49. J.E. Westin, M. Andersson, M. Lundblad, and M.A. Cenci Persistent changes in striatal gene expression induced by long-term l-DOPA treatment in a rat model of Parkinson's disease Eur. J. Neurosci. 14 2001 1171 1176